Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon Adjunctive Therapy for Parkinson's Disease with Motor Fluctuations
NCT04542499Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Tavapadon + Levodopa with Placebo + Levodopa (2 arms). Primary endpoint: Change From Baseline in the Total 'On' Time Without Troublesome Dyskinesia at 26 weeks. Started Sep 2020; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04542499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542499.